Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease.
The cell surface proteins CD20 and CD52 differ significantly in their structures and are expressed on the majority of B cells. Both circulating CD20 (cCD20) and circulating CD52 (cCD52) have been recently documented in patients with chronic lymphocytic leukaemia. A retrospective study to establish whether cCD20 and/or cCD52 were detectable in patients with lymphoma, and the clinical associations of these soluble antigens if detected, was conducted. cCD20 and cCD52 levels were analysed in a cohort of 65 patients with non-Hodgkin's lymphoma (NHL) and 37 with Hodgkin's disease (HD). Patients with NHL had elevated pretherapy levels of cCD20 and cCD52 compared with normal individuals. Patients with HD had significantly lower than normal pretherapy levels of both cCD20 and cCD52. cCD20 levels were marginally elevated post-therapy in NHL patients while in patients with HD, cCD20 levels remained significantly lower than normal after therapy. Serum cCD52 levels became significantly lower than normal post-therapy in NHL patients, and remained significantly lower than normal in HD patients. No predictive effects were found for pretherapy or post-therapy levels of cCD52 on survival for either cohort of patients. Post-therapy cCD20 levels independently highly correlated with survival in patients with NHL. Prospective evaluation will be required to establish if cCD20 and cCD52 may be used as biomarkers in the diagnosis, prognostic categorization, and monitoring of the clinical course in patients with lymphoma. The clinical significance of circulating antigen in patients receiving monoclonal antibody therapy directed against CD20 and/or CD52 warrants study.
Giles
Francis J
FJ
Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. fgiles@mdanderson.org
Vose
Julie M
JM
Do
Kim-Anh
KA
Johnson
Marcella M
MM
Manshouri
Taghi
T
Bociek
Gregory
G
Bierman
Philip J
PJ
O'Brien
Susan M
SM
Keating
Michael J
MJ
Kantarjian
Hagop M
HM
Armitage
James O
JO
Albitar
Maher
M
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD / Q000097:blood*; D018951:Antigens, CD20 / Q000097:blood*; D000951:Antigens, Neoplasm / Q000097:blood*; D001402:B-Lymphocytes / Q000276:immunology*; D015415:Biomarkers / Q000097:blood; D000074301:CD52 Antigen; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D006023:Glycoproteins / Q000097:blood*; D006689:Hodgkin Disease / Q000188:drug therapy / Q000276:immunology* / Q000401:mortality; D006801:Humans; D016015:Logistic Models; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000276:immunology* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D018709:Statistics, Nonparametric; D015996:Survival Rate; D016896:Treatment Outcome
D015703:Antigens, CD; D018951:Antigens, CD20; D000951:Antigens, Neoplasm; D015415:Biomarkers; D000074301:CD52 Antigen; C000613862:CD52 protein, human; D006023:Glycoproteins